-
Je něco špatně v tomto záznamu ?
Fast facts: CAR T-cell therapy in diffuse large B-cell lymphoma : a practical resource for nurses
Richard J. Buka, Dee Moloney
- Publikováno
- Basel : S. Karger, 2021
- Stránkování
- 96 stran : ilustrace, tabulky
Jazyk angličtina Země Německo
Typ dokumentu příručky
Knihovny.cz ISBN
9783318069358
plný text - pouze pro uživatele NLK
Karger Fast Facts e-book
Knihovny.cz E-zdroje
- MeSH
- difúzní velkobuněčný B-lymfom terapie MeSH
- imunoterapie adoptivní MeSH
- Publikační typ
- příručky MeSH
Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine.Table of Contents:• DLBCL: an overview• CAR T cells• CAR T-cell products• Delivering CAR T-cell therapy and managing patient expectations• CAR T-cell therapy-related toxicities
CAR T-cell therapy in diffuse large B-cell lymphoma
Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma. ISBN 9783318070248 Knihovny.cz
Print version record
- 000
- 02021nam a22003255u 4500
- 001
- krg280784
- 003
- CZ-PrNML
- 005
- 20220627103030.0
- 006
- m o d
- 007
- cr unu
- 008
- 211130s2021 gw a o 001 0 eng d
- 009
- eBK
- 020 __
- $a 9783318069358
- 035 __
- $a (OCoLC)1274246615
- 040 __
- $a UKSKG $b cze $c UKSKG $b ABA008 $d ABA008
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Buka, Richard J.
- 245 10
- $a Fast facts: CAR T-cell therapy in diffuse large B-cell lymphoma : $b a practical resource for nurses / $c Richard J. Buka, Dee Moloney
- 246 13
- $a CAR T-cell therapy in diffuse large B-cell lymphoma
- 260 __
- $a Basel : $b S. Karger, $c 2021
- 300 __
- $a 96 stran : $b ilustrace, tabulky
- 520 __
- $a Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine.Table of Contents:• DLBCL: an overview• CAR T cells• CAR T-cell products• Delivering CAR T-cell therapy and managing patient expectations• CAR T-cell therapy-related toxicities
- 588 0_
- $a Print version record
- 650 07
- $a hematologie a transfuzní lékařství $7 nlk20040147649 $2 mednas
- 650 07
- $a onkologie $7 nlk20040148136 $2 mednas
- 650 07
- $a ošetřovatelství $7 nlk20040148150 $2 mednas
- 650 07
- $a difúzní velkobuněčný B-lymfom $x terapie $7 D016403 $2 czmesh
- 650 07
- $a imunoterapie adoptivní $7 D016219 $2 czmesh
- 655 _7
- $a příručky $7 D020479 $2 czmesh
- 700 1_
- $a Moloney, Dee
- 776 08
- $i Print version: $t Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma $z 9783318070248
- 856 40
- $u https://www.medvik.cz/link/access.do?source=portal&url=https://www.karger.com/Book/Home/280784 $y plný text - pouze pro uživatele NLK $z Karger Fast Facts e-book
- 910 __
- $a ABA008 $b ebook $t l $y x
- 990 __
- $a 20211220 $b ABA008
- 991 __
- $a 20220627103029 $b ABA008
- 999 __
- $a ok $b medvik21 $g 1760277 $s 225206
- BAS __
- $a EBK
